Skip to main content
Erschienen in: Inflammation 6/2014

01.12.2014

Protective Effects of Chelerythrine Against Lipopolysaccharide-Induced Endotoxic Shock in Mice

verfasst von: Xiaofeng Niu, Qingli Mu, Weifeng Li, Huimin Huang, Huan Yao, Huani Li

Erschienen in: Inflammation | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Chelerythrine (CHE), a quaternary benzo[c]phenanthridine alkaloid, exhibits a wide spectrum of pharmacological effects. Although CHE has been used to treat various diseases, the protective effects of CHE on lipopolysaccharide (LPS)-induced endotoxic shock have not been explored. The aims of the study were to investigate the protective effects of CHE on LPS-induced endotoxic shock in mice and clarify the mechanism of the effects. We found that pretreatment with CHE (1, 5, and 10 mg/kg, po) at 1 and 12 h before injected intraperitoneally with 1 mg/kg LPS markedly decreased the production of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and myeloperoxidase (MPO) and attenuated the lung histopathological changes. Meanwhile, the effects were dependent on the inhibition of the expression of p65 nuclear factor κB (NF-κB). The protective effects of CHE on LPS-induced endotoxic shock can be attributed to attenuating inflammatory cytokines and inhibition of the expression of NF-κB.
Literatur
1.
Zurück zum Zitat Aoki, K., T. Tajima, Y. Yabushita, A. Nakamura, U. Nezu, M. Takahashi, M. Kimura, and Y. Terauchi. 2008. A novel initial codon mutation of the thiazide-sensitive Na-Cl cotransporter gene in a Japanese patient with Gitelman’s syndrome. Endocrine Journal 55: 557.PubMedCrossRef Aoki, K., T. Tajima, Y. Yabushita, A. Nakamura, U. Nezu, M. Takahashi, M. Kimura, and Y. Terauchi. 2008. A novel initial codon mutation of the thiazide-sensitive Na-Cl cotransporter gene in a Japanese patient with Gitelman’s syndrome. Endocrine Journal 55: 557.PubMedCrossRef
2.
Zurück zum Zitat Freudenberg, M., and C. Galanos. 1990. Bacterial lipopolysaccharides: structure, metabolism and mechanisms of action. International Reviews of Immunology 6: 207–221.PubMedCrossRef Freudenberg, M., and C. Galanos. 1990. Bacterial lipopolysaccharides: structure, metabolism and mechanisms of action. International Reviews of Immunology 6: 207–221.PubMedCrossRef
3.
Zurück zum Zitat Bone, R.C., C.J. Grodzin, and R.A. Balk. 1997. Sepsis: a new hypothesis for pathogenesis of the disease process. CHEST Journal 112: 235–243.CrossRef Bone, R.C., C.J. Grodzin, and R.A. Balk. 1997. Sepsis: a new hypothesis for pathogenesis of the disease process. CHEST Journal 112: 235–243.CrossRef
4.
Zurück zum Zitat He, M., H.Y. Lau, S.W. Ng, and M. Bhatia. 2007. Chemokines in acute inflammation: regulation, function and therapeutic strategies. International Journal of Integrative Biology 1: 18. He, M., H.Y. Lau, S.W. Ng, and M. Bhatia. 2007. Chemokines in acute inflammation: regulation, function and therapeutic strategies. International Journal of Integrative Biology 1: 18.
5.
Zurück zum Zitat Lappin, E., and A.J. Ferguson. 2009. Gram-positive toxic shock syndromes. The Lancet Infectious Diseases 9: 281–290.PubMedCrossRef Lappin, E., and A.J. Ferguson. 2009. Gram-positive toxic shock syndromes. The Lancet Infectious Diseases 9: 281–290.PubMedCrossRef
6.
Zurück zum Zitat Jansen, M.J., T. Hendriks, M.T. Vogels, J.W. van der Meer, and R.J.A. Goris. 1996. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Critical Care Medicine 24: 1196–1202.PubMedCrossRef Jansen, M.J., T. Hendriks, M.T. Vogels, J.W. van der Meer, and R.J.A. Goris. 1996. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Critical Care Medicine 24: 1196–1202.PubMedCrossRef
7.
Zurück zum Zitat Neurath, M.F., I. Fuss, M. Pasparakis, L. Alexopoulou, S. Haralambous, K.H. Meyer zum Büschenfelde, W. Strober, and G. Kollias. 1997. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. European Journal of Immunology 27: 1743–1750.PubMedCrossRef Neurath, M.F., I. Fuss, M. Pasparakis, L. Alexopoulou, S. Haralambous, K.H. Meyer zum Büschenfelde, W. Strober, and G. Kollias. 1997. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. European Journal of Immunology 27: 1743–1750.PubMedCrossRef
8.
Zurück zum Zitat Blenman, K.R.M., F.R. Bahjat, L.L. Moldawer, and L. Morel. 2004. Aberrant signaling in the TNFα/TNF receptor 1 pathway of the NZM2410 lupus-prone mouse. Clinical Immunology 110: 124–133.PubMedCrossRef Blenman, K.R.M., F.R. Bahjat, L.L. Moldawer, and L. Morel. 2004. Aberrant signaling in the TNFα/TNF receptor 1 pathway of the NZM2410 lupus-prone mouse. Clinical Immunology 110: 124–133.PubMedCrossRef
9.
Zurück zum Zitat Ma, X. 2001. TNF-α and IL-12: a balancing act in macrophage functioning. Microbes and Infection 3: 121–129.PubMedCrossRef Ma, X. 2001. TNF-α and IL-12: a balancing act in macrophage functioning. Microbes and Infection 3: 121–129.PubMedCrossRef
10.
Zurück zum Zitat Yoshimoto, T., K. Nakanishi, S. Hirose, K. Hiroishi, H. Okamura, Y. Takemoto, A. Kanamaru, T. Hada, T. Tamura, and E. Kakishita. 1992. High serum IL-6 level reflects susceptible status of the host to endotoxin and IL-1/tumor necrosis factor. The Journal of Immunology 148: 3596–3603.PubMed Yoshimoto, T., K. Nakanishi, S. Hirose, K. Hiroishi, H. Okamura, Y. Takemoto, A. Kanamaru, T. Hada, T. Tamura, and E. Kakishita. 1992. High serum IL-6 level reflects susceptible status of the host to endotoxin and IL-1/tumor necrosis factor. The Journal of Immunology 148: 3596–3603.PubMed
11.
Zurück zum Zitat Damas, P., D. Ledoux, M. Nys, Y. Vrindts, D. De Groote, P. Franchimont, and M. Lamy. 1992. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Annals of Surgery 215: 356.PubMedCentralPubMedCrossRef Damas, P., D. Ledoux, M. Nys, Y. Vrindts, D. De Groote, P. Franchimont, and M. Lamy. 1992. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Annals of Surgery 215: 356.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Bhatia, M., and S. Moochhala. 2004. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. The Journal of Pathology 202: 145–156.PubMedCrossRef Bhatia, M., and S. Moochhala. 2004. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. The Journal of Pathology 202: 145–156.PubMedCrossRef
13.
Zurück zum Zitat LaRosa, S.P., and S.M. Opal. 2008. Sepsis strategies in development. Clinics in Chest Medicine 29: 735–747.PubMedCrossRef LaRosa, S.P., and S.M. Opal. 2008. Sepsis strategies in development. Clinics in Chest Medicine 29: 735–747.PubMedCrossRef
14.
Zurück zum Zitat Klosterhalfen, B., K. Hörstmann-Jungemann, P. Vogel, S. Flohé, F. Offner, C.J. Kirkpatrick, and P.C. Heinrich. 1992. Time course of various inflammatory mediators during recurrent endotoxemia. Biochemical Pharmacology 43: 2103–2109.PubMedCrossRef Klosterhalfen, B., K. Hörstmann-Jungemann, P. Vogel, S. Flohé, F. Offner, C.J. Kirkpatrick, and P.C. Heinrich. 1992. Time course of various inflammatory mediators during recurrent endotoxemia. Biochemical Pharmacology 43: 2103–2109.PubMedCrossRef
15.
Zurück zum Zitat Martich, G.D., A.J. Boujoukos, and A.F. Suffredini. 1993. Response of man to endotoxin. Immunobiology 187: 403–416.PubMedCrossRef Martich, G.D., A.J. Boujoukos, and A.F. Suffredini. 1993. Response of man to endotoxin. Immunobiology 187: 403–416.PubMedCrossRef
16.
Zurück zum Zitat Szarka, R.J., N. Wang, L. Gordon, P.N. Nation, and R.H. Smith. 1997. A murine model of pulmonary damage induced by lipopolysaccharide via intranasal instillation. Journal of Immunological Methods 202: 49–57.PubMedCrossRef Szarka, R.J., N. Wang, L. Gordon, P.N. Nation, and R.H. Smith. 1997. A murine model of pulmonary damage induced by lipopolysaccharide via intranasal instillation. Journal of Immunological Methods 202: 49–57.PubMedCrossRef
17.
Zurück zum Zitat Tracey, K.J., B. Beutler, S.F. Lowry, J. Merryweather, S. Wolpe, I.W. Milsark, R.J. Hariri, T.J. Fahey, A. Zentella, and J.D. Albert. 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234: 470–474.PubMedCrossRef Tracey, K.J., B. Beutler, S.F. Lowry, J. Merryweather, S. Wolpe, I.W. Milsark, R.J. Hariri, T.J. Fahey, A. Zentella, and J.D. Albert. 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234: 470–474.PubMedCrossRef
18.
Zurück zum Zitat Kruidenier, La., and H. Verspaget. 2002. Oxidative stress as a pathogenic factor in inflammatory bowel disease—radicals or ridiculous? Alimentary Pharmacology & Therapeutics 16: 1997–2015.CrossRef Kruidenier, La., and H. Verspaget. 2002. Oxidative stress as a pathogenic factor in inflammatory bowel disease—radicals or ridiculous? Alimentary Pharmacology & Therapeutics 16: 1997–2015.CrossRef
19.
Zurück zum Zitat Takeuchi, K., T. Yasuhiro, Y. Asada, and Y. Sugawa. 1998. Role of nitric oxide in pathogenesis of aspirin-induced gastric mucosal damage in rats. Digestion 59: 298–307.PubMedCrossRef Takeuchi, K., T. Yasuhiro, Y. Asada, and Y. Sugawa. 1998. Role of nitric oxide in pathogenesis of aspirin-induced gastric mucosal damage in rats. Digestion 59: 298–307.PubMedCrossRef
20.
Zurück zum Zitat Klebanoff, S.J. 2005. Myeloperoxidase: friend and foe. Journal of Leukocyte Biology 77: 598–625.PubMedCrossRef Klebanoff, S.J. 2005. Myeloperoxidase: friend and foe. Journal of Leukocyte Biology 77: 598–625.PubMedCrossRef
21.
Zurück zum Zitat Kim, I.-S., Y.-J. Park, S.-J. Yoon, and H.-B. Lee. 2010. Ephedrannin A and B from roots of Ephedra sinica inhibit lipopolysaccharide-induced inflammatory mediators by suppressing nuclear factor-κB activation in RAW 264.7 macrophages. International Immunopharmacology 10: 1616–1625.PubMedCrossRef Kim, I.-S., Y.-J. Park, S.-J. Yoon, and H.-B. Lee. 2010. Ephedrannin A and B from roots of Ephedra sinica inhibit lipopolysaccharide-induced inflammatory mediators by suppressing nuclear factor-κB activation in RAW 264.7 macrophages. International Immunopharmacology 10: 1616–1625.PubMedCrossRef
22.
Zurück zum Zitat Wise, G.E., and S. Yao. 2003. Expression of tumour necrosis factor-alpha in the rat dental follicle. Archives of Oral Biology 48: 47–54.PubMedCrossRef Wise, G.E., and S. Yao. 2003. Expression of tumour necrosis factor-alpha in the rat dental follicle. Archives of Oral Biology 48: 47–54.PubMedCrossRef
23.
Zurück zum Zitat Heinzel, F.P., R.M. Rerko, P. Ling, J. Hakimi, and D.S. Schoenhaut. 1994. Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infection and Immunity 62: 4244–4249.PubMedCentralPubMed Heinzel, F.P., R.M. Rerko, P. Ling, J. Hakimi, and D.S. Schoenhaut. 1994. Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infection and Immunity 62: 4244–4249.PubMedCentralPubMed
24.
Zurück zum Zitat Suzuki, K., K. Tateda, T. Matsumoto, F. Gondaira, S. Tsujimoto, and K. Yamaguchi. 2000. Effects of interaction between Escherichia coli verotoxin and lipopolysaccharide on cytokine induction and lethality in mice. Journal of Medical Microbiology 49: 905–910.PubMed Suzuki, K., K. Tateda, T. Matsumoto, F. Gondaira, S. Tsujimoto, and K. Yamaguchi. 2000. Effects of interaction between Escherichia coli verotoxin and lipopolysaccharide on cytokine induction and lethality in mice. Journal of Medical Microbiology 49: 905–910.PubMed
25.
Zurück zum Zitat Yadav, S.K., B. Adhikary, S. Chand, B. Maity, S.K. Bandyopadhyay, and S. Chattopadhyay. 2012. Molecular mechanism of indomethacin-induced gastropathy. Free Radical Biology and Medicine 52: 1175–1187.PubMedCrossRef Yadav, S.K., B. Adhikary, S. Chand, B. Maity, S.K. Bandyopadhyay, and S. Chattopadhyay. 2012. Molecular mechanism of indomethacin-induced gastropathy. Free Radical Biology and Medicine 52: 1175–1187.PubMedCrossRef
26.
Zurück zum Zitat Remick, D.G., G.R. Bolgos, J. Siddiqui, J. Shin, and J.A. Nemzek. 2002. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17: 463–467.PubMedCrossRef Remick, D.G., G.R. Bolgos, J. Siddiqui, J. Shin, and J.A. Nemzek. 2002. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17: 463–467.PubMedCrossRef
27.
Zurück zum Zitat Ito, H., M. Takazoe, Y. Fukuda, T. Hibi, K. Kusugami, A. Andoh, T. Matsumoto, T. Yamamura, J. Azuma, and N. Nishimoto. 2004. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 126: 989–996.PubMedCrossRef Ito, H., M. Takazoe, Y. Fukuda, T. Hibi, K. Kusugami, A. Andoh, T. Matsumoto, T. Yamamura, J. Azuma, and N. Nishimoto. 2004. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 126: 989–996.PubMedCrossRef
28.
Zurück zum Zitat Luo, J., J. Cao, X. Jiang, and H. Cui. 2010. Effect of low molecular weight heparin rectal suppository on experimental ulcerative colitis in mice. Biomedicine & Pharmacotherapy 64: 441–445.CrossRef Luo, J., J. Cao, X. Jiang, and H. Cui. 2010. Effect of low molecular weight heparin rectal suppository on experimental ulcerative colitis in mice. Biomedicine & Pharmacotherapy 64: 441–445.CrossRef
29.
Zurück zum Zitat Reinisch, W., C. Gasché, W. Tillinger, J. Wyatt, C. Lichtenberger, M. Willheim, C. Dejaco, T. Waldhör, S. Bakos, and H. Vogelsang. 1999. Clinical relevance of serum interleukin-6 in Crohn’s disease: single point measurements, therapy monitoring, and prediction of clinical relapse. The American Journal of Gastroenterology 94: 2156–2164.PubMedCrossRef Reinisch, W., C. Gasché, W. Tillinger, J. Wyatt, C. Lichtenberger, M. Willheim, C. Dejaco, T. Waldhör, S. Bakos, and H. Vogelsang. 1999. Clinical relevance of serum interleukin-6 in Crohn’s disease: single point measurements, therapy monitoring, and prediction of clinical relapse. The American Journal of Gastroenterology 94: 2156–2164.PubMedCrossRef
30.
Zurück zum Zitat Buraczynska, M., L. Jozwiak, P. Ksiazek, E. Borowicz, and P. Mierzicki. 2007. Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Translational Research 150: 101–105.PubMedCrossRef Buraczynska, M., L. Jozwiak, P. Ksiazek, E. Borowicz, and P. Mierzicki. 2007. Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Translational Research 150: 101–105.PubMedCrossRef
31.
Zurück zum Zitat Benamar, K., E.B. Geller, and M.W. Adler. 2002. Effect of a μ-opioid receptor-selective antagonist on interleukin-6 fever. Life Sciences 70(18): 2139–2145.PubMedCrossRef Benamar, K., E.B. Geller, and M.W. Adler. 2002. Effect of a μ-opioid receptor-selective antagonist on interleukin-6 fever. Life Sciences 70(18): 2139–2145.PubMedCrossRef
32.
Zurück zum Zitat Beffa, D.C., A.J. Fischman, S.P. Fagan, V.F. Hamrahi, K.W. Paul, M. Kaneki, Y.-M. Yu, R.G. Tompkins, and E.A. Carter. 2011. Simvastatin treatment improves survival in a murine model of burn sepsis: role of interleukin 6. Burns 37: 222–226.PubMedCentralPubMedCrossRef Beffa, D.C., A.J. Fischman, S.P. Fagan, V.F. Hamrahi, K.W. Paul, M. Kaneki, Y.-M. Yu, R.G. Tompkins, and E.A. Carter. 2011. Simvastatin treatment improves survival in a murine model of burn sepsis: role of interleukin 6. Burns 37: 222–226.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Cheng, L.N., X.L. Huang, W. Shi, J.Y. Xiang, and H.T. Gan. 2009. Tetrandrine ameliorates dextran-sulfate-sodium-induced colitis in mice through inhibition of nuclear factor-κB activation. International Journal of Colorectal Disease 24: 5–12.PubMedCrossRef Cheng, L.N., X.L. Huang, W. Shi, J.Y. Xiang, and H.T. Gan. 2009. Tetrandrine ameliorates dextran-sulfate-sodium-induced colitis in mice through inhibition of nuclear factor-κB activation. International Journal of Colorectal Disease 24: 5–12.PubMedCrossRef
Metadaten
Titel
Protective Effects of Chelerythrine Against Lipopolysaccharide-Induced Endotoxic Shock in Mice
verfasst von
Xiaofeng Niu
Qingli Mu
Weifeng Li
Huimin Huang
Huan Yao
Huani Li
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 6/2014
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-9929-7

Weitere Artikel der Ausgabe 6/2014

Inflammation 6/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.